{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"The percentage of people who are still alive.","groups":[{"description":"First participant received: CFZ 27mg/m\\^2, Bendamustine 70mg/m\\^2, Dexamethasone 20mg; Second participant received: CFZ 36mg/m\\^2, Bendamustine 70mg/m\\^2, Dexamethasone 20mg; Third participant received: CFZ 36mg/m\\^2, Bendamustine 90mg/m\\^2, Dexamethasone 20mg; Fourth participant received: CFZ 45mg/m\\^2, Bendamustine 90mg/m\\^2, Dexamethasone 20mg; Fifth participant and all other participants received: CFZ 56mg/m\\^2, Bendamustine 90mg/m\\^2, Dexamethasone 20mg.\n\nData was collected and analyzed as one arm for this single-arm study. Additionally, presented as one arm to protect the confidentiality of the first four participants.","id":"OG000","title":"CFZ With Bendamustine and Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 6.5 Years","title":"Overall Survival (OS) Rate","type":"SECONDARY","unitOfMeasure":"Participants"}